naltrexone and levodopa

naltrexone has been researched along with levodopa in 21 studies

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19902 (9.52)18.7374
1990's3 (14.29)18.2507
2000's10 (47.62)29.6817
2010's6 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carrupt, PA; Crivori, P; Cruciani, G; Testa, B1
Jolivette, LJ; Ward, KW1
Lombardo, F; Obach, RS; Waters, NJ1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Ceresoli, G; Groppetti, A; Mandelli, V; Parenti, M1
Malone, MH; Namba, MM; Quock, RM2
Ané, M; Blin, O; Fabre, N; Montastruc, JL; Poulik, J; Rascol, A; Rascol, O; Sabatini, U; Senard, JM1
Flumerfelt, BA; Newman, DD; Rajakumar, N; Stoessl, AJ1
Inoue, H1
Hobart, J; Katzenschlager, R; Lees, AJ; Manson, AJ1
Brotchie, JM; Crossman, AR; Fox, SH; Henry, B1
Bédard, PJ; Grégoire, L; Samadi, P1
Bédard, PJ; Di Paolo, T; Grégoire, L; Hadj Tahar, A; Rouillard, C; Samadi, P1
Benabid, AL; Berger, F; Buggia, V; Gilbert, F; Lévesque, D; Sgambato-Faure, V1
Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK1
Brotchie, JM; DeHaven, RN; DeHaven-Hudkins, DL; Dolle, RE; Fox, SH; Goodman, A; Johnston, TH; Koprich, JB; Le Bourdonnec, B; Little, PJ1
Grabowski, J; Green, CE; Lindsay, JA; Moeller, FG; Rathnayaka, NS; Schmitz, JM; Stotts, AL1

Trials

2 trial(s) available for naltrexone and levodopa

ArticleYear
Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:4

    Topics: Aged; Bromocriptine; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Naltrexone; Neurologic Examination; Parkinson Disease

1994
A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone.
    Drug and alcohol dependence, 2014, Mar-01, Volume: 136

    Topics: Adolescent; Adult; Benzhydryl Compounds; Carbidopa; Central Nervous System Stimulants; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Data Interpretation, Statistical; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Modafinil; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Patient Compliance; Secondary Prevention; Treatment Outcome; Young Adult

2014

Other Studies

19 other study(ies) available for naltrexone and levodopa

ArticleYear
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
    Journal of medicinal chemistry, 2000, Jun-01, Volume: 43, Issue:11

    Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
    Journal of pharmaceutical sciences, 2005, Volume: 94, Issue:7

    Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution

2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment.
    The Journal of pharmacology and experimental therapeutics, 1990, Volume: 253, Issue:3

    Topics: Adenylyl Cyclases; Animals; Apomorphine; Corpus Striatum; Drug Interactions; Hydroxydopamines; Levodopa; Male; Morphine; Naltrexone; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Opioid

1990
Narcotic antagonist potentiation of L-DOPA in the reversal of reserpine induced catalepsy.
    Proceedings of the Western Pharmacology Society, 1980, Volume: 23

    Topics: Animals; Catalepsy; Drug Synergism; Humans; Levodopa; Male; Mice; Naloxone; Naltrexone; Narcotic Antagonists; Reserpine; Time Factors

1980
Effects of narcotic antagonists on L-dopa reversal of reserpine-induced catalepsy and blepharoptosis in mice.
    Life sciences, 1981, Apr-06, Volume: 28, Issue:14

    Topics: Animals; Blepharoptosis; Catalepsy; Drug Antagonism; Drug Synergism; Humans; Kinetics; Levodopa; Male; Mice; Naloxone; Naltrexone; Reserpine

1981
A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease.
    Neuroreport, 1997, Feb-10, Volume: 8, Issue:3

    Topics: Animals; Apomorphine; Functional Laterality; Hippocampus; Infusions, Parenteral; Levodopa; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Rotation

1997
Effects of naltrexone on the accumulation of L-3, 4-dihydroxyphenylalanine and 5-hydroxy-L-tryptophan and on the firing rate induced by acute ethanol administration.
    European journal of pharmacology, 2000, Oct-20, Volume: 406, Issue:3

    Topics: 5-Hydroxytryptophan; Animals; Corpus Striatum; Dose-Response Relationship, Drug; Ethanol; Levodopa; Male; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Rats; Rats, Sprague-Dawley

2000
High dose naltrexone for dyskinesias induced by levodopa.
    Journal of neurology, neurosurgery, and psychiatry, 2001, Volume: 70, Issue:4

    Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Naltrexone; Reproducibility of Results

2001
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
    Experimental neurology, 2001, Volume: 171, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Female; Hypokinesia; Levodopa; Male; Morphinans; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Posture; Receptors, Opioid, delta; Receptors, Opioid, mu

2001
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
    Neuropharmacology, 2003, Volume: 45, Issue:7

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Endorphins; Female; Levodopa; Macaca fascicularis; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission

2003
Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Neuropharmacology, 2005, Volume: 49, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesias; Female; Levodopa; Macaca fascicularis; Motor Activity; Naltrexone; Narcotic Antagonists; Ovariectomy; Parkinsonian Disorders; Statistics, Nonparametric; Time Factors

2005
Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats.
    Journal of neuropathology and experimental neurology, 2005, Volume: 64, Issue:11

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic Agents; AIDS-Related Complex; Amphetamine; Analgesics, Non-Narcotic; Animals; Antiparkinson Agents; Behavior, Animal; Carrier Proteins; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Functional Laterality; Homer Scaffolding Proteins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; Oxidopamine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation

2005
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Neuropharmacology, 2010, Volume: 58, Issue:1

    Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors

2010
The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:7

    Topics: Animals; Antiparkinson Agents; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Receptors, Opioid, mu

2011